Patrick Maisonneuve - Istituto Europeo di Oncologia

Patrick Maisonneuve
Group Leader,
Direttore, unita di epidemiologia clinica
Divisione di Epidemiologia e Biostatistica
Istituto Europeo di Oncologia
Via Ripamonti, 435 - 20141 Milano
T +390257489822
E [email protected]
Titoli di Studio
1985 Laurea in Ingegneria presso l’Istituto Nazionale di Scienze Applicate (INSA), Lione (Francia)
1982 Diploma Universitario di Tecnologia, Istituto universitario di Tecnologia IUT-2, Lione (Francia)
1979 Diploma di maturità (Baccalauréat), seria C (Matematica), Liceo Ampere bourse, Lione (Francia)
Corsi e certificati
1989 Corso estivo d’epidemiologia-2, New England Epidemiology Summer Program, Tuft University, Medford (USA)
1988 Corso estivo d’epidemiologia-1, New England Epidemiology Summer Program, Tuft university, Medford (USA)
Esperienza professionale
2003- oggi Direttore dell’Unità di Epidemiologia clinica, Istituto Europeo di Oncologia (IEO), Milano
1994-2003 Vice-direttore, Divisione di Epidemiologia e Biostatistica, IEO, Milano
1991-1994 Epidemiologo senior e responsabile SIS, Divisione di Epidemiologia e Biostatistica, IEO, Milano
1986-1991 Assistente epidemiologo, Agenzia Internazionale di Ricerca sul Cancro (WHO-IARC), Lione (Francia).
Attività di Ricerca
Epidemiologia dei tumori ed altre patologie croniche tramite studi caso-controllo, studi di coorti e meta-analisi.
Prevenzione e identificazione di fattori prognostici dei tumori tramite studi randomizzati e studi clinici osservazionali sui pazienti affetti
da tumore.
Sviluppo di modelli di rischi.
Premi ed Onorificenze
2001 Clinical Assistant Professor of Community and Preventive Medicine, New York Medical College, Valhalla (USA)
Pubblicazioni
Autore di più di 380 pubblicazioni scientifiche (h-index 72).
1.
Maisonneuve P, Disalvatore D, Rotmensz N, Curigliano G, Colleoni M, Dellapasqua S, Pruneri G, Mastropasqua MG, Luini A, Bassi
F, Pagani G, Viale G, Goldhirsch A. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2negative) intrinsic breast cancer subtypes. Breast Cancer Res 2014;16:R65.
2.
Lowenfels AB, Maisonneuve P. Can We Prevent Pancreatic Disease? Clin Gastroenterol Hepatol 2014;12:1645-6.
3.
Veronesi G, Maisonneuve P, Spaggiari L, Rampinelli C, Pardolesi A, Bertolotti R, Filippi N, Bellomi M. Diagnostic Performance of
Low-Dose Computed Tomography Screening for Lung Cancer over Five Years. J Thorac Oncol 2014;9:935-9.
4.
Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer
(ELIOT): a randomised controlled equivalence trial. Lancet Oncol 2013;14:1269-77.
5.
Veronesi G, Maisonneuve P, Rampinelli C, et al. Computed tomography screening for lung cancer: Results of ten years of annual
screening and validation of cosmos prediction model. Lung Cancer 2013;82:426-30.
6.
Gnagnarella P, Maisonneuve P, Bellomi M, et al. Red meat, Mediterranean diet and lung cancer risk among heavy smokers in the
COSMOS screening study. Ann Oncol 2013;24:2606-11.
7.
Cancello G, Maisonneuve P, Rotmensz N, et al. Progesterone receptor loss identifies Luminal B breast cancer subgroups at
higher risk of relapse. Ann Oncol 2013;24:661-8
8.
Maisonneuve P, Marshall BC, Knapp EA, et al. Cancer Risk in Cystic Fibrosis: A 20-Year Nationwide Study From the United States.
J Natl Cancer Inst 2013;10:122-9.
9.
Veronesi G, Maisonneuve P, Bellomi M, et al. Estimating overdiagnosis in low-dose computed tomography screening for lung
cancer: a cohort study. Ann Intern Med 2012;157:776-84.
10. Maisonneuve P, Bagnardi V, Bellomi M, et al. Lung cancer risk prediction to select smokers for screening CT - A model based on
the Italian COSMOS trial. Cancer Prev Res (Phila) 2011;4:1778-89.
11. Maisonneuve P, Lowenfels AB, Bueno-de-Mesquita HB, et al. Past Medical History and Pancreatic Cancer Risk: Results From a
Multicenter Case-Control Study. Annals Epidemiol 2010;20:92-8.
12. Veronesi U, Maisonneuve P, Rotmensz N, et al.; Italian Tamoxifen Study Group.Tamoxifen for the prevention of breast cancer:
late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst
2007;99:727-37.
13. Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of
5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005;330:932-5.
14. Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid Function and Mortality in Patients Treated for Hyperthyroidism. JAMA
2005;294:71-80.
15. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international
collaborative study. Lancet 1999;354:93-9.
16. Franklyn JA, Maisonneuve P, Sheppard MC, et al. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl
J Med 1998;338:712-8.
17. Neglia JP, FitzSimmons SC, Maisonneuve P, et al. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and
Cancer Study Group. N Engl J Med 1995;332:494-9.
18. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study
Group. N Engl J Med 1993;328:1433-7.
Letture a congressi e corsi
9th European Postgraduate School In Gastroenterology, Prague, Apr 12-13, 2013
Epidemiology of Pancreatic Cancer
21st ETS, Birmingham, May 28, 2013
Comparison of different risk models and definition of the best target population and screening interval
European School of Abdomino-pelvic surgery in Gynecologic Oncology, IEO, May 13, 2013
Epidemiology of Endometrial Cancer
44th meeting of the European Pancreatic Club (EPC), Prague, Jun 20, 2012
Epidemiological trends in pancreatic diseases
Diagnosi e Terapia dell'Adenocarcinoma Pancreatico, Parma, May 11, 2012
Epidemiology and Biological Behaviour of Pancreatic Cancer
3a Conferenza Nazionale sulla Ricerca Sanitaria, Villa Erba Cernobbio (CO), Nov 12-13, 2012
Diagnosi Precoce del Tumore del Polmone Tramite TC a Basso Dosaggio e miRNAs